Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Post-prandial glucose excursions remain elevated in most patients with diabetes even when normal fasting plasma glucose levels have been achieved. In 39 patients with type 2 diabetes who had attained basal normoglycaemia by therapy with diet alone, a sulphonylurea, a basal insulin supplement or basal plus prandial insulin the mean glycosylated haemoglobin (HbA1) values were at the upper end (mean +/- 1SD, 8.1 +/- 1.1%) of the normal range (5.0-8.2%). Miglitol, an alpha-glucosidase inhibitor, given in a dose of 50 mg three times a day was studied in a double blind randomized crossover study. In diet and sulphonylurea treated patients, a mean 25% reduction of the post-prandial plasma glucose excursions was obtained whereas in ultralente treated patients miglitol appeared to reduce basal plasma glucose levels (p < 0.006). Side effects were limited to minor gastrointestinal disturbances, usually ameliorating after the first week of therapy. Alpha-glucosidase inhibition to prevent post-prandial glycaemia may have a role in patients in whom sulphonylurea or diet therapy has been used to obtain normal basal glucose concentrations.

Type

Journal article

Journal

Diabetes Res

Publication Date

12/1991

Volume

18

Pages

149 - 153

Keywords

1-Deoxynojirimycin, Biomarkers, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diet, Diabetic, Eating, Female, Fructosamine, Glucosamine, Glycated Hemoglobin A, Glycoside Hydrolase Inhibitors, Hexosamines, Humans, Hypoglycemic Agents, Imino Pyranoses, Insulin, Insulin, Long-Acting, Lipoproteins, HDL, Lipoproteins, LDL, Male, Middle Aged, Reference Values, Time Factors, Triglycerides